Table 2.
Maternal characteristics for HIV‐positive infants
| Infant identifier | Maternal age (years) | Identified as high risk at screening | High‐risk reason | ARVs prior to pregnancy (ever) | ARV regimen during pregnancy | Adherence concerns during pregnancy?a | Maternal CD4 (cells/mm3) | Maternal VL (copies/mL) |
|---|---|---|---|---|---|---|---|---|
| A | 28.7 | Yes | Less than 8 weeks maternal ART in pregnancy, poor ART adherence in pregnancy. | No | EFV/TDF/FTCc | Yesb | 804 | 9436 |
| B | 20.6 | Yes | Detectable maternal viral load at last test | Yes | LPV/r/TDF/FTC | Yes | 264 | 23,912 |
| C | 22.8 | Yes | Less than 8 weeks maternal ART in pregnancy | Yes | EFV/TDF/FTC | No | 336 | 67 |
| D | 21.4 | Yes | Detectable maternal viral load at last test | Yes | EFV/TDF/FTC | No | 184 | 125,093 |
| E | 29.2 | Yes | Less than 8 weeks maternal ART in pregnancy, maternal CD4<250 in pregnancy | No | EFV/TDF/FTC | No | 258 | 355 |
| F | 23 | Yes | Less than 8 weeks maternal ART in pregnancy | No | None | NA | 650 | 81,982 |
| G | 28.5 | Yes | Less than 8 weeks maternal ART in pregnancy | No | None | NA | 199 | 25,666 |
| H | 32.2 | Yes | Detectable maternal viral load at last test | Yes | EFV/TDF/FTC | No | 177 | 54,974 |
| I | 30.4 | Yes | Less than 8 weeks maternal ART in pregnancy | No | EFV/TDF/FTC | No | 791 | 1389 |
| J | 26.5 | Yes | Less than 8 weeks maternal ART in pregnancy | No | EFV/TDF/FTC | No | 626 | 2467 |
| K | 29.9 | Yes | Less than 8 weeks maternal ART in pregnancy | No | None | NA | 227 | 2349 |
| L | 27.4 | Yes | Less than 8 weeks maternal ART in pregnancy | No | None | NA | Unknown | Unknown |
| Median | 27.95 | 264 | 9436 |
a
Identified at enrolment.
b
Stopped after 2 weeks (more than 1 month prior to delivery) of ARV due to side effects.
c
EFV, efavirenz; TDF, tenofovir; FTC, emtricitabine; LPV/r, lopinavir/ritonavir.